Purpura, Thrombocytopaenic, Idiopathic — Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect
Citation(s)
A Randomized, Open-label, Five-period, Balanced Crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag Powder for Oral Suspension (PfOS) Formulation Relative to the Commercial 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in Healthy Adult Subjects